
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity is well positioned because its platform reaches roughly 80% of U.S. physicians, creating a durable network moat that supports sticky Marketing, Hiring, and Workflow Solutions and gives pharma customers efficient access to highly targeted medical audiences. The business is also proving strong operating leverage, with revenue of $174.5M (+4% y/y), adjusted EBITDA of $88.9M at a 50.9% margin, and free cash flow of $91M, while AI Search has already become an eight-figure bookings product with 16 of the top 20 pharma companies buying in. Management’s raised FY27 revenue outlook to $678M-$683M, plus expanding health system adoption and improving AI unit costs, suggests the company can sustain growth while investing for a larger AI-driven opportunity.
Bears say
Doximity is exposed to a concentrated revenue base, with over 90% of sales tied to marketing solutions sold to pharma and health systems, leaving results highly dependent on cyclical drug budgets rather than on diversified demand. Its core customer spend is pressured by Most Favored Nation pricing uncertainty, Inflationary Reduction Act-related reprioritization, FDA scrutiny, and upcoming LOEs, while most contracts are only 12 months or less, so renewals and bookings can shift quickly. Although the platform reaches 85% of all doctors, low switching costs, data-privacy limits, cybersecurity risk, and the possibility that AI investments fail to offset weaker HCP pharma marketing create an unattractive risk/reward profile.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Doximity (DOCS) Forecast
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares